JAZZ N Stock Overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Jazz Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2,027.24 |
| 52 Week High | US$2,027.24 |
| 52 Week Low | US$2,027.24 |
| Beta | 0.61 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| JAZZ N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -7.0% | -1.5% |
| 1Y | n/a | -5.5% | 0.5% |
Return vs Industry: Insufficient data to determine how JAZZ N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how JAZZ N performed against the MX Market.
Price Volatility
| JAZZ N volatility | |
|---|---|
| JAZZ N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.4% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: JAZZ N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine JAZZ N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,800 | Bruce Cozadd | www.jazzpharma.com |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.
Jazz Pharmaceuticals plc Fundamentals Summary
| JAZZ N fundamental statistics | |
|---|---|
| Market cap | Mex$114.82b |
| Earnings (TTM) | Mex$6.91b |
| Revenue (TTM) | Mex$63.86b |
16.6x
P/E Ratio1.8x
P/S RatioIs JAZZ N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JAZZ N income statement (TTM) | |
|---|---|
| Revenue | US$3.83b |
| Cost of Revenue | US$284.13m |
| Gross Profit | US$3.55b |
| Other Expenses | US$3.14b |
| Earnings | US$414.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.65 |
| Gross Margin | 92.59% |
| Net Profit Margin | 10.82% |
| Debt/Equity Ratio | 153.0% |
How did JAZZ N perform over the long term?
See historical performance and comparison